People: Inhibitex, Inc. (INHX.O)
INHX.O on Consolidated Issue listed on NASDAQ Capital Market
1.04USD
9 Feb 2010
1.04USD
9 Feb 2010
Price Change (% chg)
$-0.01 (-0.96%)
$-0.01 (-0.96%)
Prev Close
$1.04
$1.04
Open
--
--
Day's High
$1.04
$1.04
Day's Low
$1.01
$1.01
Volume
22,187
22,187
Avg. Vol
49,720
49,720
52-wk High
$1.33
$1.33
52-wk Low
$0.21
$0.21
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
| Henos, Michael | 59 | 2001 | Chairman of the Board |
| Plumb, Russell | 50 | 2007 | President, Chief Executive Officer, Chief Financial Officer, Director |
| Patti, Joseph | 44 | 2007 | Chief Scientific Officer, Senior Vice President - Research and Development |
| Henson, Geoffrey | 61 | 2007 | Senior Vice President - Drug Development |
| Barrett, M. James | 66 | 2002 | Director |
| Medford, Russell | 54 | 1997 | Director |
| Preminger, Marc | 59 | 2003 | Director |
| Willard, A. Keith | 68 | 2005 | Director |
| Cerrone, Gabriele | 37 | 2007 | Director |
| McGuigan, Christopher | 50 | 2007 | Director |
Biographies
| Name | Description |
|---|---|
| Henos, Michael | Mr. Michael A. Henos is Chairman of the Board of Inhibitex Inc since April 2001. Mr. Henos also served as Chairman of the Board from July 1997 to January 2000. Since 1993, Mr. Henos has served as Managing General Partner of Alliance Technology Ventures, L.P., a venture capital firm. From 1991 to 2001, Mr. Henos served as a General Partner of Aspen Ventures, a venture capital partnership. He currently serves as Chairman of the Board of Directors of AtheroGenics, Inc., and as a director of Genoptix, Inc., a publicly-held biopharmaceutical company. He is also a member of the Board of Directors of the following privately-held biopharmaceutical companies: GlycoMimetics, Inc. and Sensys Medical, Inc. Mr. Henos received a B.S. in Economics and a M.B.A. in Finance from the University of California, Los Angeles. |
| Plumb, Russell | Mr. Russell H. Plumb is President, Chief Executive Officer, Chief Financial Officer, Director of Inhibitex Inc. He is President, Chief Executive Officer and Chief Financial Officer of Inhibitex on December 30, 2006 and served as Vice President, Finance and Administration and Chief Financial Officer from August 2000 through December 2006. From December 1999 to July 2000, Mr. Plumb served as Chief Financial Officer of Emory Vision, a healthcare company. From 1994 to November 1999, he served as Chief Financial Officer and Vice President, Finance of Serologicals Corporation, a publicly-held biopharmaceutical company. Mr. Plumb received both a Bachelor of Commerce and a M.B.A. from the University of Toronto. Mr. Plumb has received designations as a certified public accountant in Michigan and Georgia. |
| Patti, Joseph | Joseph M. Patti, M.S.P.H., Ph.D. is Chief Scientific Officer, Senior Vice President - Research and Development of Inhibitex Inc since 2007 and prior to that served as the Company’s Vice President, Preclinical Development and Chief Scientific Officer from 1998 to 2007 and Vice President of Research and Development from 2005 to 2007. From 1994 to 1998, Dr. Patti was an Assistant Professor at Texas A&M’s Institute of Biosciences and Technology. From 1996 to 1998, he also served on the faculty at the University of Texas Health Science Center Graduate School of Biomedical Sciences. Dr. Patti received a B.S. in Microbiology from the University of Pittsburgh, an M.S.P.H. from the University of Miami, School of Medicine and a Ph.D. in Biochemistry from the University of Alabama at Birmingham. |
| Henson, Geoffrey | Mr. Geoffrey W. Henson, Ph.D. has served as Senior Vice President, Drug Development, of Inhibitex, since the acquisition of FermaVir Pharmaceuticals, Inc. in September 2007. Dr. Henson was previously President, Chief Executive Officer, Secretary and a director of FermaVir from August 2005 to September 2007. From 2003 to March 2005, Dr. Henson was a pharmaceutical consultant. He was a co-founder of AnorMED, a Canadian biopharmaceutical company, where he was employed in various management capacities from 1996-2003, most recently as COO. Prior to co-founding AnorMED, he held a number of management and scientific positions in the Biomedical Research Group at Johnson Matthey from 1985-1996. From 1982-1985, Dr Henson was a researcher and member of the Basel Institute for Immunology in Basel, Switzerland. Dr. Henson obtained his M.S. and Ph.D. in Biochemistry from New Mexico State University, and B.S. in Chemistry from Dickinson College. |
| Barrett, M. James | M. James Barrett, Ph.D. is Director of Inhibitex Inc. He has served as a general partner of NEA Partners 10 Limited Partnership, the general partner of New Enterprise Associates 10 Limited Partnership, a venture capital fund, since August 2001. From January 1997 to August 2001, he served as Chairman and Chief Executive Officer of Sensors for Medicine and Science, Inc., a medical device company, which he founded in 1997. He continues to serve as the Chairman of its Board of Directors. Dr. Barrett also serves on the Boards of Directors of two publicly-held biopharmaceutical companies: Taragacept, Inc. and YM Biosciences, Inc., and the Boards of several privately-held biopharmaceutical companies. Dr. Barrett received a B.S. in Chemistry from Boston College, a Ph.D. in Biochemistry from the University of Tennessee and a M.B.A. from the University of Santa Clara. |
| Medford, Russell | Mr. Russell M. Medford, M.D., Ph.D. is Director of Inhibitex Inc. He has served, since April 1, 2009, as Chairmen and President of Salutria Pharmaceuticals, Inc., a biopharmaceutical company. From 1995 to April 1, 2009 Dr. Medford served as President, Chief Executive Officer and Director of AtheroGenics, Inc., a publicly-held pharmaceutical company. On September 15, 2008, an involuntary petition under Chapter 7 of the United States Bankruptcy Code was filed against AtheroGenics, Inc. by certain holders of its 4.5% Convertible Notes Due 2008 in the United States Bankruptcy Court for the Northern district of Georgia (the “Bankruptcy Court”). On October 6, 2008, AtheroGenics, Inc. consented to the bankruptcy filing and moved in the Bankruptcy Court to convert the Chapter 7 case to a case under Chapter 11 of the United States Bankruptcy Code. Dr. Medford serves on the Biotechnology Industry Organization’s (“BIO”) Board of Directors and BIO Emerging Companies Section Governing Body, and he served as Chairman of the Georgia BioMedical Partnership from 2004 to 2007 and the Georgia Biotechnology Industry Organization Board of Directors. Dr. Medford was an Associate Professor of Medicine and Director of Molecular Cardiology at the Emory University School of Medicine, and currently holds the appointment of Adjunct Clinical Professor of Medicine. Dr. Medford received a B.A. from Cornell University, and a M.D. with Distinction and a Ph.D. in Molecular and Cell Biology from the Albert Einstein College of Medicine. |
| Preminger, Marc | Mr. Marc L. Preminger, FSA, MAAA, is Director of Inhibitex Inc. He served in various capacities with CIGNA Corporation, a healthcare insurance company, from 1977 until his retirement in September 2002, the most recent of which was Senior Vice President and Chief Financial Officer of Cigna Healthcare. Mr. Preminger received a B.A. in Economics from Lafayette College and a Masters of Actuarial Science from Georgia State University. |
| Willard, A. Keith | Mr. A. Keith Willard is Director of Inhibitex Inc. He served from 1993 to 1999 as Chairman and Chief Executive Officer of Zeneca, Inc., a multinational pharmaceutical company. Prior to that, he served in several capacities with ICI Canada, including President and a member of its Board of Directors. He has been retired since October 1999. He received a B.A. in Sociology from Concordia University and is a graduate of the Advanced Executive Management Institute at McGill University. |
| Cerrone, Gabriele | Mr. Gabriele M. Cerrone is Director of Inhibitex Inc since September 2007. From March 1999 to January 2005, Mr. Cerrone served as a Senior Vice President of Investments of Oppenheimer & Co. Inc., a financial services firm. Between May 2001 and May 2003, Mr. Cerrone served on the board of directors of Siga Technologies, Inc. Mr. Cerrone co-founded Xenomics, Inc., a molecular diagnostic company, and served as Co-Chairman from July 2005 until November 2006. Mr. Cerrone also co-founded FermaVir Pharmaceuticals and served as Chairman of the Board from August 2005 until September 2007. Mr. Cerrone is a co-founder of Synergy Pharmaceuticals, Inc. as well as Callisto Pharmaceuticals, Inc. and currently serves as Chairman of the Board and a consultant to both publicly-held biopharmaceutical companies. Mr. Cerrone is the managing partner of Panetta Partners, Ltd., a Colorado limited partnership, that is a private investor in both public and private venture capital in the life sciences and technology arena as well as real estate. Mr. Cerrone graduated from New York University’s Leonard N. Stern School of Business with a degree in Finance. |
| McGuigan, Christopher | Christopher McGuigan, M.Sc., Ph.D., is Director of Inhibitex Inc. He served as a member of the Board of Directors of FermaVir from August 2005 until it was acquired by Inhibitex in September 2007. Since 1995, Dr. McGuigan has been Professor, Welsh School of Pharmacy, Chairman of Departmental Research Committee and Director of Research, Head of Medicinal Chemistry. He is also the Chemistry Editor for Antiviral Chemistry and Chemotherapy, a member of the Editorial Board for the Journal of Medicinal Chemistry and is the immediate past President and a board member of the International Society for Antiviral Research. Dr. McGuigan received a B.S. and Ph.D. in Anticancer Drug Design from the University of Birmingham. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
| Henos, Michael | -- |
| Plumb, Russell | 939,243 |
| Patti, Joseph | 495,327 |
| Henson, Geoffrey | 468,204 |
| Barrett, M. James | -- |
| Medford, Russell | -- |
| Preminger, Marc | -- |
| Willard, A. Keith | -- |
| Cerrone, Gabriele | -- |
| McGuigan, Christopher | -- |
As Of 30 Dec 2008
Options Compensation
| Name | Options | Value |
|---|---|---|
| Henos, Michael | 0 | 0 |
| Plumb, Russell | 198,154 | 746,341 |
| Patti, Joseph | 310,863 | 1,357,267 |
| Henson, Geoffrey | 0 | 0 |
| Barrett, M. James | 0 | 0 |
| Medford, Russell | 0 | 0 |
| Preminger, Marc | 0 | 0 |
| Willard, A. Keith | 0 | 0 |
| Cerrone, Gabriele | 0 | 0 |
| McGuigan, Christopher | 0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
| QVT ASSOCIATES GP L L C | 25,000 | $0.72 |
| QVT ASSOCIATES GP L L C | 75,000 | $0.73 |
| QVT ASSOCIATES GP L L C | 23,000 | $0.89 |
| QVT ASSOCIATES GP L L C | 50,000 | $0.99 |
| QVT ASSOCIATES GP L L C | 2,000 | $0.96 |
| QVT ASSOCIATES GP L L C | 12,300 | $0.96 |
| QVT ASSOCIATES GP L L C | 300 | $1.00 |
| QVT ASSOCIATES GP L L C | 16,292 | $0.98 |
| QVT ASSOCIATES GP L L C | 13,000 | $0.99 |
| QVT ASSOCIATES GP L L C | 11,700 | $0.99 |
| QVT ASSOCIATES GP L L C | 11,000 | $0.98 |
| QVT ASSOCIATES GP L L C | 85,000 | $0.99 |
| QVT ASSOCIATES GP L L C | 9,500 | $0.98 |
| QVT ASSOCIATES GP L L C | 19,000 | $0.99 |
| QVT ASSOCIATES GP L L C | 100,000 | $1.00 |
| QVT ASSOCIATES GP L L C | 13,000 | $1.00 |
| QVT ASSOCIATES GP L L C | 71,000 | $0.99 |
| QVT ASSOCIATES GP L L C | 46,000 | $0.99 |
| QVT ASSOCIATES GP L L C | 48,000 | $0.99 |
| QVT ASSOCIATES GP L L C | 79,000 | $1.00 |
| QVT ASSOCIATES GP L L C | 50,000 | $0.99 |
| QVT ASSOCIATES GP L L C | 5,000 | $0.99 |
| QVT ASSOCIATES GP L L C | 2,600 | $0.97 |
| QVT ASSOCIATES GP L L C | 14,880 | $0.99 |
| QVT ASSOCIATES GP L L C | 27,556 | $0.99 |
© Copyright 2010 Thomson Reuters
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
